Drug Trial Radar · NCT03438396
A Trial of Tisotumab Vedotin in Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Jun 12, 2018
Primary completion
Feb 6, 2020
Study completion Aug 2, 2022
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab; European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian Gynaecological Oncology Group; Gynecologic Oncology Group
- First posted
- Feb 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.
Conditions
- Cervical Cancer
Interventions
tisotumab vedotinDrug
All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC)Time frame: From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Arizona Oncology Associate - Biltmore Cancer Center
Phoenix, Arizona
UCLA Dept. of OBGYN
Los Angeles, California
Southern Baptist Hospital of Florida, Inc
Jacksonville, Florida
University of Miami Miller School of Medicine
Miami, Florida
University of Gynecologic Oncology
Atlanta, Georgia
Community Hospital East
Indianapolis, Indiana
Louisville Oncology
Louisville, Kentucky
Baystate Medical Center
Springfield, Massachusetts
Women's Cancer Center of Nevada
Las Vegas, Nevada
MD Anderson Cancer Center at Cooper University Hospital
Camden, New Jersey
University of New Mexico Comprehensive Cancer Center (UNMCCC)
Albuquerque, New Mexico
University of Cincinnati
Cincinnati, Ohio
The Ohio State University Wexner Medical Center
Hilliard, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma
Abington Memorial Hospital
Willow Grove, Pennsylvania
Bon Secours Saint Francis Cancer Center
Greenville, South Carolina
UT Health McGovern Medical School
Houston, Texas
Froedtert & Medical College Clinics
Milwaukee, Wisconsin
AZ Sint-Jan Brugge-Oostende av
Bruges, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
Algemeen Ziekenhuis Maria MiddelaresMedical Oncology - IKG
Ghent, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZLeuvenGynaecologische oncologie
Leuven, Belgium
Centre Hospitalier de l'Ardenne
Libramont, Belgium
CHC SAINT Montlegia
Liège, Belgium
CHU de LIEGE/ Oncologie Médicale, domaine universitaire du Sart Tilman
Liège, Belgium
CHU UCL Namur site de Sainte Elisabeth
Namur, Belgium
Fakultni Nemocnice Brno
Brno, Czechia
Fakultni nemocnice Olomouc Onkologic
Olomouc, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Nemocnice Na Bulovce, Gynekologicko-porodnicka kl
Prague, Czechia
Aalborg Universitetshospital
Aalborg, Denmark
Rigshospitalet
Copenhagen, Denmark
Kliniken Essen-Mitte
Düsseldorf, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Klinikum der Universität München
Münich, Germany
Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii
Bologna, Italy
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.